Author(s)

Natasha Takova¹, Alexander Otsetov^2*

¹Department of Urology, Centre Hospitalier Saint Dié des Vosges, Saint-Dié des Vosges, France.
²Department of Pathology, Institute for Medical Biosciences, Umeå University, Umeå, Sweden.

Paraneoplastic syndromes (PS) represent a large spectrum of symptoms, associated with malignant diseases. PS can be diagnosed in asymptomatic patients with occult carcinoma, clinically active cancer, and during clinical remission, suggesting a recurrence of the neoplasm. The underlying mechanisms of PS are not completely understood but several authors have suggested that the increased production of biologically active immune factors and cytokines from the neoplastic cells may underlie the etiology of PS. Although rare, the renal involvement of patients with prostatic carcinoma has been reported. The most common paraneoplastic-associated glomerulopathy in prostatic cancer is the membranoproliferative glomerulonephritis with nephrotic syndrome (NS). In this review, we aimed to discuss the incidence of nephrotic syndrome secondary to prostatic carcinoma, its challenging diagnosis, clinical manifestation, and treatment.

Paraneoplastic Syndromes, Prostatic Carcinoma, Malignancy-Associated Glomerulonephritis, Nephrotic Syndrome, (Bio)Marker

Takova, N. and Otsetov, A. (2017) Nephrotic Sydrome Can Be a Marker for Prostatic Carcinoma. Modern Research in Inflammation, 6, 29-36. doi: 10.4236/mri.2017.64004.